Head to Head Survey: Baxalta (BXLT) vs. Kadmon (KDMN)
Baxalta (NYSE: BXLT) and Kadmon (NYSE:KDMN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.
Insider and Institutional Ownership
51.9% of Kadmon shares are owned by institutional investors. 8.4% of Kadmon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Baxalta and Kadmon’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Baxalta and Kadmon’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Kadmon||$26.06 million||10.77||-$208.75 million||($1.75)||-2.04|
Baxalta has higher earnings, but lower revenue than Kadmon. Kadmon is trading at a lower price-to-earnings ratio than Baxalta, indicating that it is currently the more affordable of the two stocks.
Baxalta pays an annual dividend of $0.28 per share and has a dividend yield of 0.6%. Kadmon does not pay a dividend. Baxalta pays out 23.5% of its earnings in the form of a dividend.
This is a breakdown of recent ratings and target prices for Baxalta and Kadmon, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Kadmon has a consensus target price of $9.75, suggesting a potential upside of 173.11%. Given Kadmon’s higher probable upside, analysts clearly believe Kadmon is more favorable than Baxalta.
Kadmon beats Baxalta on 6 of the 11 factors compared between the two stocks.
Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta’s categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.
Receive News & Ratings for Baxalta Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxalta Inc and related companies with MarketBeat.com's FREE daily email newsletter.